7/15
09:05 am
tnxp
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Low
Report
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
7/14
06:06 pm
tnxp
Tonix Pharmaceuticals (TNXP) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
Medium
Report
Tonix Pharmaceuticals (TNXP) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
7/13
08:53 am
tnxp
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) [Yahoo! Finance]
Medium
Report
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) [Yahoo! Finance]
7/13
07:11 am
tnxp
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® [Yahoo! Finance]
High
Report
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® [Yahoo! Finance]
7/13
07:00 am
tnxp
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Medium
Report
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
6/30
01:02 pm
tnxp
Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation [Seeking Alpha]
Low
Report
Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation [Seeking Alpha]
6/29
12:41 pm
tnxp
Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating [Seeking Alpha]
Low
Report
Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating [Seeking Alpha]
6/29
07:58 am
tnxp
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) [Yahoo! Finance]
6/29
07:25 am
tnxp
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Medium
Report
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
6/26
07:03 am
tnxp
Tonix Pharmaceuticals (TNXP) was upgraded by Raymond James Financial, Inc. to "strong-buy".
Medium
Report
Tonix Pharmaceuticals (TNXP) was upgraded by Raymond James Financial, Inc. to "strong-buy".
6/24
06:00 pm
tnxp
Tonix Pharmaceuticals (TNXP) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Low
Report
Tonix Pharmaceuticals (TNXP) is now covered by Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
6/13
08:09 pm
tnxp
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate [Yahoo! Finance]
6/12
04:22 am
tnxp
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 [Yahoo! Finance]
6/11
07:00 am
tnxp
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Medium
Report
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
6/8
10:04 am
tnxp
Why Is TNXP Stock Rising Today? [Yahoo! Finance]
Low
Report
Why Is TNXP Stock Rising Today? [Yahoo! Finance]
6/8
07:19 am
tnxp
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives [Yahoo! Finance]
6/8
07:00 am
tnxp
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Medium
Report
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
5/28
04:30 pm
tnxp
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Low
Report
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
5/28
02:06 pm
tnxp
Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants [Yahoo! Finance Canada]
Low
Report
Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants [Yahoo! Finance Canada]
5/27
07:22 am
tnxp
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology [Yahoo! Finance]
5/27
07:00 am
tnxp
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Medium
Report
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
5/26
07:00 am
tnxp
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Low
Report
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
5/20
08:02 pm
tnxp
TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. Patients [Yahoo! Finance]
Low
Report
TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. Patients [Yahoo! Finance]
5/14
07:00 am
tnxp
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
Low
Report
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
5/12
04:30 pm
tnxp
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
Medium
Report
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May